ReviewCurrent opinion in pharmacology2004
Recent advances in the pharmacology of neurological gene therapy.
Review in Current opinion in pharmacology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Gene Therapy Tools for Brain Diseases.Frontiers in pharmacology · 2019Review
- Single vs. combination immunotherapeutic strategies for glioma.Expert opinion on biological therapy · 2017Review
- Safety profile of gutless adenovirus vectors delivered into the normal brain parenchyma: implications for a glioma phase 1 clinical trial.Human gene therapy methods · 2012Article
- Efficacy of nonviral gene transfer in the canine brain.Journal of neurosurgery · 2007Article
- Novel liposomal formulation for targeted gene delivery.Pharmaceutical research · 2007Article
- Regulatable gene expression systems for gene therapy.Current gene therapy · 2006Review
- Human gene therapy and imaging in neurological diseases.European journal of nuclear medicine and molecular imaging · 2005Review
- Regulatable gene expression systems for gene therapy applications: progress and future challenges.Molecular therapy : the journal of the American Society of Gene Therapy · 2005Review
- Full deacylation of polyethylenimine dramatically boosts its gene delivery efficiency and specificity to mouse lung.Proceedings of the National Academy of Sciences of the United States of America · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The choice of vectors, transgenes, regulatory elements, delivery approaches and the capacity to transduce the appropriate target cell type all influence the effectiveness of gene therapy for neurological diseases. Furthermore, even if many strategies are sound and effective in experimental animals, issues relating to side effects of gene therapy, longevity of therapeutic transgene expression and diffusion throughout the brain can limit the clinical potential of gene therapy. During the past 12-18 months, there have been significant advances in the following areas: the capacity to target vectors to predetermined cells types; the development of gene therapy approaches for the treatment of dominant inherited and neurodegenerative diseases; the capacity to achieve systemic delivery of viral vectors to the brain; and the development of viral vectors to model neurological diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.